As a result, before I move on to my list of the four most promising pharmaceutical companies in the global immunology market, I would like to once again ask you to pay attention to my approach to ...

The company targets markets in immunology, oncology ... While we acknowledge the potential of biotech companies, our conviction lies in the belief that AI stocks hold greater promise for ...

Biotechnology is a rapidly evolving sector with significant advancements anticipated between 2025 and 2035. As innovations in ...

Just a few months after raising $200 million in third-round financing, immunology specialist Zenas ... acceleration in the number of biotech companies seeking public listings after a two-year ...

In 2025, the Company has repurchased a total of 8,146,000 shares in the open market, amounting to nearly HK$30 million . This reflects confidence in the Company's business outlook and underscores ...

China is teeming with promising science in areas such as oncology and immunology ... comes not only from other VC firms or even biotech companies. It’s coming from big pharma, he said.

This is not about doing it all but about translating external trends into actionable strategies that keep companies ... the future of biotech The convergence of oncology and immunology is not ...

About Zenas BioPharma, Inc. Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based ...

Johnson & Johnson executive praises China's biotech innovation in oncology and immunology, highlighting potential future ...